(NEXSTAR) – Americans looking to get a booster shot against the coronavirus this fall don’t just have one new option – they’ve got two. Both Moderna and Pfizer have a new FDA-authorized COVID-19 ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses the differences between ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers ...

Recipients of the Pfizer mRNA vaccine experienced more all-cause deaths within the first 100 days post-vaccination than those who received the Moderna shot, a new study of 1.47 million people found.

Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a ...

Pfizer has a deep lineup and pipeline, generates consistent results, and pays dividends. Moderna is on the verge of key approvals and has exciting pipeline candidates in the works. One of these ...